Göblyös Anikó, Ijzerman Ad P
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Leiden, The Netherlands.
Biochim Biophys Acta. 2011 May;1808(5):1309-18. doi: 10.1016/j.bbamem.2010.06.013. Epub 2010 Jun 27.
Allosteric ligands for G protein-coupled receptors (GPCRs) may alter receptor conformations induced by an orthosteric ligand. These modulators can thus fine-tune classical pharmacological responses. In this review we will describe efforts to synthesize and characterize allosteric modulators for one particular GPCR subfamily, the adenosine receptors. There are four subtypes of these receptors: A(1), A(2A), A(2B) and A(3). Allosteric enhancers for the adenosine A(1) receptor may have anti-arrythmic and anti-lipolytic activity. They may also act as analgesics and neuroprotective agents. A(3) allosteric enhancers are thought to be beneficial in ischemic conditions or as antitumor agents. We will summarize recent developments regarding the medicinal chemistry of such compounds. Most data have been and are published about the adenosine A(1) and A(3) receptor, whereas limited or no information is available for the A(2A) and A(2B) receptor, respectively. Receptor mutation studies are also discussed, as they may shed light on the localization of the allosteric binding sites. This article is part of a Special Issue entitled: "Adenosine Receptors".
G蛋白偶联受体(GPCRs)的变构配体可能会改变由正构配体诱导的受体构象。因此,这些调节剂可以微调经典的药理反应。在这篇综述中,我们将描述为合成和表征一种特定GPCR亚家族——腺苷受体的变构调节剂所做的努力。这些受体有四种亚型:A(1)、A(2A)、A(2B)和A(3)。腺苷A(1)受体的变构增强剂可能具有抗心律失常和抗脂解活性。它们还可能用作镇痛药和神经保护剂。A(3)变构增强剂被认为在缺血条件下有益或可作为抗肿瘤剂。我们将总结关于此类化合物药物化学的最新进展。大多数数据已经并正在发表,涉及腺苷A(1)和A(3)受体,而关于A(2A)和A(2B)受体的信息分别有限或没有。还讨论了受体突变研究,因为它们可能有助于揭示变构结合位点的定位。本文是名为“腺苷受体”的特刊的一部分。